Skip to main content

Advertisement

Fig. 4 | Breast Cancer Research

Fig. 4

From: Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging

Fig. 4

89Zr-trastuzumab positron emission tomography (PET) predicts tumor response to treatment in JIMT-1 xenografts. Untreated (left) and 7-day (middle) or 14-day (right) treated JIMT-1 tumors imaged with fluorodeoxyglucose (FDG) (a). The same group of mice were imaged with 89Zr-trastuzumab after 48 h post injection (b). Volumes of interest (VOIs) drawn on the tumors displayed lower accumulation of 89Zr-trastuzumab in treated groups compared to control but no change in FDG-PET tumor uptake was observed across the cohorts (c). Percentage change in tumor volume correlated with 89Zr-trastuzumab uptake (d). T, tumor; L, liver; d, days

Back to article page